<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944526</url>
  </required_header>
  <id_info>
    <org_study_id>2016-10/02</org_study_id>
    <nct_id>NCT02944526</nct_id>
  </id_info>
  <brief_title>The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial</brief_title>
  <official_title>The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Saint-Jean, Bruxelles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital St Luc, Brussels</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique Saint-Jean, Bruxelles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting with subacute, less than 6 months of evolution, adhesive capsulitis are&#xD;
      randomly attributed to the control or study group. Both groups receive a series of 3&#xD;
      suprascapular nerve blocks under ultrasound guidance with either 5ml saline or 5ml&#xD;
      ropivacaine 2mg/ml ( ref) at 1 week interval. Testing consists of glenohumeral range of&#xD;
      motion (ROM) (anterior elevation, lateral elevation, external and internal rotation) measured&#xD;
      by goniometer, Constant score and visual analog scale (VAS) pain score. Evaluations are done&#xD;
      immediately before and one hour after every suprascapular block and at 4 weeks after the&#xD;
      third suprascapular block.&#xD;
&#xD;
      All suprascapular nerve blocks are performed by one physician and the evaluations are done by&#xD;
      a occupational therapist or MD experienced in glenohumeral function evaluations. All&#xD;
      practitioners are blinded to the assigned group.&#xD;
&#xD;
      All patients continue their pre-study treatment of physiotherapy and per os pain medication.&#xD;
      Patients keep a record of analgesics and NSAID use during the trial. Drop-out rate is&#xD;
      measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Adhesive capsulitis is a painful and debilitating condition affecting adult&#xD;
      shoulders. Although relatively rare the condition is more common in diabetic patients and&#xD;
      effective pain diminishing treatments without the use of corticosteroids are needed.&#xD;
&#xD;
      Methods and Material: Patients presenting with subacute, less than 6 months of evolution,&#xD;
      adhesive capsulitis are randomly attributed to the control or study group. Both groups&#xD;
      receive a series of 3 successive suprascapular nerve blocks under live ultrasound guidance&#xD;
      with either 5ml saline or 5ml ropivacaine 2mg/ml conducted at 1 week interval. Testing&#xD;
      consists of glenohumeral ROM (anterior elevation, lateral elevation, external and internal&#xD;
      rotation) measured by goniometer, Constant score, VAS pain score. Evaluations are done&#xD;
      immediately before and one hour after every &quot;suprascapular block&quot; and at 4 weeks after the&#xD;
      third suprascapular block.&#xD;
&#xD;
      All suprascapular blocks are performed by one physician and the evaluations by either a&#xD;
      occupational therapist or MD experienced in glenohumeral function evaluations. All&#xD;
      practitioners are blinded to the assigned group.&#xD;
&#xD;
      All patients continue their physiotherapy, consisting of electrotherapy, range of motion,&#xD;
      stretching and strengthening exercises and their per os medication. Patients keep record of&#xD;
      analgesics and NSAID use during the trial. Drop-out rate is measured during the entire study&#xD;
      protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 16, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in constant shoulder score</measure>
    <time_frame>at 0, 1, 2, and 6 weeks</time_frame>
    <description>the total constant score ranges from 0 to 100 points, with higher scores indicative of better function. The score is divided into four sections: pain, activity of daily living, ROM and strength</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of pain intensity score</measure>
    <time_frame>at 0,1,2 and 6 weeks</time_frame>
    <description>pain intensity measured by visual analog scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in gleno-humeral joint range of motion (ROM)</measure>
    <time_frame>at 0,1,2, and 6 weeks</time_frame>
    <description>Shoulder flexion, abduction, external rotation and internal rotation measured with goniometer with the patient in standing position</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Adhesive Capsulitis</condition>
  <condition>Frozen Shoulder</condition>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Ropivacaine Suprascapular Nerve Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.&#xD;
3 successive blocks are realized at 1 week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Suprascapular Nerve Block</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.&#xD;
3 successive blocks are realized at 1 week interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Monohydrochloride</intervention_name>
    <description>Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml</description>
    <arm_group_label>Ropivacaine Suprascapular Nerve Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Concentrate</intervention_name>
    <description>Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline</description>
    <arm_group_label>Placebo Suprascapular Nerve Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subacute adhesive capsulitis: pain evolving for less than 6 months before enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other conditions involving the shoulder ( rheumatoid or septic arthritis, Hill-Sachs&#xD;
             lesions,osteoarthritis of the shoulder, or malignancies in the shoulder region);&#xD;
&#xD;
          -  neurologic deficits affecting shoulder function in normal daily activities (such as&#xD;
             history of stroke, multiple sclerosis, parkinson disease...)&#xD;
&#xD;
          -  shoulder pain caused by cervical radiculopathy&#xD;
&#xD;
          -  a history of drug allergy to ropivaca√Øne&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  cognitive impairment with inability to fill out a protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SCHILTZ Marc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marc Schiltz, MD</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Saint-Jean, Bruxelles</investigator_affiliation>
    <investigator_full_name>Marc Schiltz, MD</investigator_full_name>
    <investigator_title>Dr Marc Schiltz MD, Head of Department Physical Medicine and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>suprascapular nerve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

